Literature DB >> 8550266

Serum total homocysteine and coronary heart disease.

E Arnesen1, H Refsum, K H Bønaa, P M Ueland, O H Førde, J E Nordrehaug.   

Abstract

BACKGROUND: Several studies have observed high plasma levels of homocysteine among patients with coronary heart disease (CHD). The only prospective study was based on US physicians, and concluded that homocysteine was associated with subsequent myocardial infarction (MI). However, the association was limited to those above a threshold level of homocysteine.
METHODS: We conducted a nested case-control study among the 21,826 subjects, aged 12-61 years, who were surveyed in the municipality of Tromsø, Norway. Among those free from MI at the screening, 123 later developed CHD. Four controls were selected for each case.
RESULTS: Level of homocysteine was higher in cases than in controls (12.7 +/- 4.7 versus 11.3 +/- 3.7 mumol/l (mean +/- SD); P = 0.002). The relative risk for a 4 mumol/l increase in serum homocysteine was 1.41 (95% confidence interval (CI): 1.16-1.71). Adjusting for possible confounders reduced the relative risk to 1.32 (95% CI: 1.05-1.65). There was no threshold level above which serum homocysteine is associated with CHD events.
CONCLUSIONS: In the general population serum total homocysteine is an independent risk factor for CHD with no threshold level.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8550266     DOI: 10.1093/ije/24.4.704

Source DB:  PubMed          Journal:  Int J Epidemiol        ISSN: 0300-5771            Impact factor:   7.196


  68 in total

Review 1.  Blood levels of homocysteine and atherosclerotic vascular disease.

Authors:  W G Christen; P M Ridker
Journal:  Curr Atheroscler Rep       Date:  2000-05       Impact factor: 5.113

2.  Hyperhomocyst(e)inemia.

Authors: 
Journal:  Curr Treat Options Cardiovasc Med       Date:  2000-02

3.  Similarities in the epidemiology of neural tube defects and coronary heart disease: is homocysteine the missing link?

Authors:  D H Stone; P McCarron; G D Smith
Journal:  J Epidemiol Community Health       Date:  1999-12       Impact factor: 3.710

Review 4.  Homocyst(e)ine and coronary heart disease: pharmacoeconomic support for interventions to lower hyperhomocyst(e)inaemia.

Authors:  Brahmajee K Nallamothu; A Mark Fendrick; Gilbert S Omenn
Journal:  Pharmacoeconomics       Date:  2002       Impact factor: 4.981

Review 5.  Hyperhomocysteinaemia and associated disease.

Authors:  R C Bakker; D P Brandjes
Journal:  Pharm World Sci       Date:  1997-06

Review 6.  Homocysteine and risk of cardiovascular disease.

Authors:  F Andreotti; F Burzotta; A Manzoli; K Robinson
Journal:  J Thromb Thrombolysis       Date:  2000-01       Impact factor: 2.300

7.  Effects of exercise training on pathological cardiac hypertrophy related gene expression and apoptosis.

Authors:  Young I Lee; Joon Y Cho; Mun H Kim; Kee B Kim; Dong J Lee; Kyu S Lee
Journal:  Eur J Appl Physiol       Date:  2006-04-01       Impact factor: 3.078

Review 8.  Genetics of the Framingham Heart Study population.

Authors:  Diddahally R Govindaraju; L Adrienne Cupples; William B Kannel; Christopher J O'Donnell; Larry D Atwood; Ralph B D'Agostino; Caroline S Fox; Marty Larson; Daniel Levy; Joanne Murabito; Ramachandran S Vasan; Greta Lee Splansky; Philip A Wolf; Emelia J Benjamin
Journal:  Adv Genet       Date:  2008       Impact factor: 1.944

Review 9.  Biomarkers related to aging in human populations.

Authors:  Eileen Crimmins; Sarinnapha Vasunilashorn; Jung Ki Kim; Dawn Alley
Journal:  Adv Clin Chem       Date:  2008       Impact factor: 5.394

10.  Risk factors for thromboembolic complications in inflammatory bowel disease: the role of hyperhomocysteinaemia.

Authors:  Bas Oldenburg; Bas A C Van Tuyl; René van der Griend; Rob Fijnheer; Gerard P van Berge Henegouwen
Journal:  Dig Dis Sci       Date:  2005-02       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.